0000899243-17-027009.txt : 20171120 0000899243-17-027009.hdr.sgml : 20171120 20171120173704 ACCESSION NUMBER: 0000899243-17-027009 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171120 FILED AS OF DATE: 20171120 DATE AS OF CHANGE: 20171120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SV LIFE SCIENCES FUND V LP CENTRAL INDEX KEY: 0001460732 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 171214885 BUSINESS ADDRESS: STREET 1: C/O SV LIFE SCIENCES ADVISERS, LLC STREET 2: ONE BOSTON PLACE, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 617-973-2708 MAIL ADDRESS: STREET 1: C/O SV LIFE SCIENCES ADVISERS, LLC STREET 2: ONE BOSTON PLACE, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SV Life Sciences Fund VI Strategic Partners, L.P. CENTRAL INDEX KEY: 0001667605 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 171214888 BUSINESS ADDRESS: STREET 1: C/O SV LIFE SCIENCES ADVISERS, LLC STREET 2: ONE BOSTON PLACE, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 617-367-8100 MAIL ADDRESS: STREET 1: C/O SV LIFE SCIENCES ADVISERS, LLC STREET 2: ONE BOSTON PLACE, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SVLSF V, LLC CENTRAL INDEX KEY: 0001644160 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 171214889 BUSINESS ADDRESS: STREET 1: C/O SV LIFE SCIENCES ADVISERS, LLC STREET 2: ONE BOSTON PLACE, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 617-367-8100 MAIL ADDRESS: STREET 1: C/O SV LIFE SCIENCES ADVISERS, LLC STREET 2: ONE BOSTON PLACE, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SV Life Sciences Fund V Strategic Partners, L.P. CENTRAL INDEX KEY: 0001482194 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 171214886 BUSINESS ADDRESS: STREET 1: C/O SV LIFE SCIENCES ADVISERS, LLC STREET 2: ONE BOSTON PLACE, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 617-973-2708 MAIL ADDRESS: STREET 1: C/O SV LIFE SCIENCES ADVISERS, LLC STREET 2: ONE BOSTON PLACE, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SV Life Sciences Fund VI, L.P. CENTRAL INDEX KEY: 0001642251 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 171214887 BUSINESS ADDRESS: STREET 1: C/O SV LIFE SCIENCES ADVISERS LLC STREET 2: ONE BOSTON PLACE, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: (617) 367-8100 MAIL ADDRESS: STREET 1: C/O SV LIFE SCIENCES ADVISERS LLC STREET 2: ONE BOSTON PLACE, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arsanis, Inc. CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 890 WINTER STREET, SUITE 230 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-819-5704 MAIL ADDRESS: STREET 1: 890 WINTER STREET, SUITE 230 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-11-20 0 0001501697 Arsanis, Inc. ASNS 0001644160 SVLSF V, LLC ONE BOSTON PLACE, SUITE 3900 201 WASHINGTON STREET BOSTON MA 02108 0 0 1 0 0001667605 SV Life Sciences Fund VI Strategic Partners, L.P. ONE BOSTON PLACE, SUITE 3900, 201 WASHINGTON STREET BOSTON MA 02108 0 0 1 0 0001642251 SV Life Sciences Fund VI, L.P. ONE BOSTON PLACE, SUITE 3900, 201 WASHINGTON STREET BOSTON MA 02108 0 0 1 0 0001482194 SV Life Sciences Fund V Strategic Partners, L.P. ONE BOSTON PLACE, SUITE 3900, 201 WASHINGTON STREET BOSTON MA 02108 0 0 1 0 0001460732 SV LIFE SCIENCES FUND V LP ONE BOSTON PLACE, SUITE 3900, 201 WASHINGTON STREET BOSTON MA 02108 0 0 1 0 Common Stock 2017-11-20 4 C 0 19128 A 19128 D Common Stock 2017-11-20 4 C 0 404 A 19532 D Common Stock 2017-11-20 4 C 0 247010 A 266542 D Common Stock 2017-11-20 4 C 0 5219 A 271761 D Common Stock 2017-11-20 4 C 0 322102 A 593863 D Common Stock 2017-11-20 4 C 0 6806 A 600669 D Common Stock 2017-11-20 4 C 0 111955 A 712624 D Common Stock 2017-11-20 4 C 0 2365 A 714989 D Common Stock 2017-11-20 4 C 0 202915 A 917904 D Common Stock 2017-11-20 4 C 0 4288 A 922192 D Common Stock 2017-11-20 4 C 0 431980 A 1354172 D Common Stock 2017-11-20 4 C 0 14789 A 1368961 D Common Stock 2017-11-20 4 P 0 483448 10.00 A 1852409 D Common Stock 2017-11-20 4 P 0 16552 10.00 A 1868961 D Series A-1 Convertible Preferred Stock 2017-11-20 4 C 0 65287 0.00 D Common Stock 19128 0 D Series A-1 Convertible Preferred Stock 2017-11-20 4 C 0 1380 0.00 D Common Stock 404 0 D Series A-2 Convertible Preferred Stock 2017-11-20 4 C 0 690259 0.00 D Common Stock 247010 0 D Series A-2 Convertible Preferred Stock 2017-11-20 4 C 0 14587 0.00 D Common Stock 5219 0 D Series B Convertible Preferred Stock 2017-11-20 4 C 0 721402 0.00 D Common Stock 322102 0 D Series B Convertible Preferred Stock 2017-11-20 4 C 0 15246 0.00 D Common Stock 6806 0 D Series C Convertible Preferred Stock 2017-11-20 4 C 0 224665 0.00 D Common Stock 111955 0 D Series C Convertible Preferred Stock 2017-11-20 4 C 0 4747 0.00 D Common Stock 2365 0 D Series D Convertible Preferred Stock 2017-11-20 4 C 0 692552 0.00 D Common Stock 202915 0 D Series D Convertible Preferred Stock 2017-11-20 4 C 0 14635 0.00 D Common Stock 4288 0 D Series D Convertible Preferred Stock 2017-11-20 4 C 0 1474348 0.00 D Common Stock 431980 0 D Series D Convertible Preferred Stock 2017-11-20 4 C 0 50477 0.00 D Common Stock 14789 0 D The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date. These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. These shares are owned directly by SV Life Sciences Fund VI, L.P. ("SVLS VI LP"). SV Life Sciences Fund VI (GP), LP ("SVLS VI GP") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI LP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SVLS VI SPP"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn, and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI SPP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. /s/ Mike Gray, as attorney-in-fact on behalf of SV Life Sciences Fund V, L.P. 2017-11-20 /s/ Mike Gray, as attorney-in-fact on behalf of SV Life Sciences Fund V Strategic Partners, L.P. 2017-11-20 /s/ Mike Gray, as attorney-in-fact on behalf of SV Life Sciences Fund VI, L.P. 2017-11-20 /s/ Mike Gray, as attorney-in-fact on behalf of SV Life Sciences Fund VI Strategic Partners, L.P 2017-11-20